BioTec CCI AG

Overview

BioTec CCI AG is a German private investment firm focusing on early-stage investments in innovative biotechnology and healthcare companies with high market potential. The firm aims to provide private investors with access to companies that are typically not available to them, leveraging its network to identify promising opportunities. The firm's investment strategy involves co-investments in companies addressing significant needs, particularly those in the early stages of development, such as post-preclinical study phases for drug candidates. These investments are usually in private, non-public companies, offering high value appreciation potential. BioTec CCI AG engages in both direct and indirect investments, including convertible loans, to build a diversified portfolio over the coming years. The team comprises experts with decades of experience in corporate management, capital investment, biotechnology, and medical technology. Notable members include Thomas Ziegelbauer, a financial expert with over 30 years in international corporations, and Hans Hinkel, a sales expert and director at Hinkel & Cie. Vermögensverwaltung AG. The supervisory board includes Michael Schwartzkopff, a lawyer and founding partner of LLR Kanzlei für Wirtschaftsrecht, and Klaus Hinkel, director at Schnigge AG and board member at Hinkel & Cie. Vermögensverwaltung AG. The network partners include Andreas Bergmann, a biochemist with 121 patents and co-founder of several biotech companies, Bernd Wegener, former chairman of the German Association of the Pharmaceutical Industry, and Metod Miklus, board member of the Marjan Miklus Foundation for the Promotion of Science and Research. BioTec CCI AG's portfolio includes investments in PAM Theragnostics GmbH, ADRENOMED AG, 4TEEN4 Pharmaceuticals GmbH, and SphingoTec GmbH. These companies are involved in developing diagnostic tools for diseases related to amidated peptide hormones, with a focus on Alzheimer's disease, and other innovative medical solutions. The firm aims to invest early in companies that make life more livable or even save lives, contributing to advancements in healthcare and medical technology.